Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.65 |
| ▸ | HPGD | P15428 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | PRNP | P04156 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23197679 | 0.88 | TDP1 (0.56) | ALDH1A1KDM4EHPGDLMNAHSD17B10 | |
| SCHEMBL5963207 | 0.83 | ALDH1A1 (0.58) | ALDH1A1KDM4EHPGDLMNAHSD17B10 | |
| SCHEMBL2319851 | 0.81 | TDP1 (0.48) | ALDH1A1KDM4EHPGDLMNAHSD17B10 | |
| SCHEMBL15271742 | 0.79 | NPC1 (1.00) | ALDH1A1KDM4EHPGDLMNAHSD17B10 | |
| SCHEMBL12669250 | 0.79 | TDP1 (0.46) | ALDH1A1KDM4EHPGDLMNAHSD17B10 | |
| SCHEMBL5539598 | 0.77 | GSK3B (0.57) | ALDH1A1KDM4EHPGDLMNAHSD17B10 | |
| SCHEMBL8532336 | 0.77 | HPGD (0.52) | ALDH1A1KDM4EHPGDLMNAHSD17B10 | |
| SCHEMBL13212958 | 0.77 | TDP1 (0.43) | ALDH1A1KDM4EHPGDLMNAHSD17B10 | |
| SCHEMBL4444240 | 0.77 | GSK3B (0.57) | ALDH1A1KDM4EHPGDLMNAHSD17B10 | |
| SCHEMBL14781240 | 0.77 | KDM4E (0.46) | ALDH1A1KDM4EHPGDLMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2732819-B1 | Compounds that enhance Atoh-1 expression | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-3027608-B1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2019-02-20 | — | — | EP | disclosed |
| US-10150761-B2 | Substituted pyridine-piperazinyl analogues as RSV antiviral compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2018-12-11 | — | — | US | disclosed |
| US-20170291891-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-12 | — | — | US | disclosed |
| US-20170136007-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | THE FEINSTEIN INST MEDICAL RES (US) | 2017-05-18 | — | — | US | disclosed |
| US-9428522-B2 | Piperazines, pharmaceutical compositions and methods of use thereof | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160168124-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-16 | — | — | US | disclosed |
| CN-105683183-A | Substituted pyridine-piperazinyl analogues as RSV antiviral compounds | 爱尔兰詹森科学公司 | 2016-06-15 | — | — | CN | disclosed |
| EP-3027608-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | Janssen Sciences Ireland UC (IE) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015014836-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | JANSSEN R&D IRELAND (IE) | 2015-02-05 | — | — | WO | disclosed |
| US-8822472-B2 | Piperazines, pharmaceutical compositions and methods of use thereof | CORNERSTONE THERAPEUTICS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | BONFANTI JEAN-FRANCOIS | 2009-09-03 | — | — | US | disclosed |
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | BONFANTI JEAN-FRANCOIS | 2009-09-03 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291891-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | MAVS, ZC3HAV1, PIR | ALDH1A1 2540/4885KDM4E 1166/4885HPGD 2904/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | ALDH1A1 355/4885KDM4E 4854/4885HPGD 3159/4885 |
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | GABRA5, GABRA4, GABRA3 | ALDH1A1 372/4885KDM4E 983/4885HPGD 1729/4885 |
| US-20160168124-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | MAVS, ZC3HAV1, PIR | ALDH1A1 2540/4885KDM4E 1166/4885HPGD 2904/4885 |
| US-20170136007-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRM5 | ALDH1A1 814/4885KDM4E 4175/4885HPGD 1280/4885 |
| US-10150761-B2 | Substituted pyridine-piperazinyl analogues as RSV antiviral compounds | MAVS, ZC3HAV1, PIR | ALDH1A1 2466/4885KDM4E 1174/4885HPGD 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.